YSYoram Sorokin

Yoram Sorokin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoram Sorokin has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interpreting coronary artery disease risk through gene-environment interactions in gene regulation

    by Anthony S Findley, Allison L Richards, Cristiano Petrini, Adnan Alazizi, Elizabeth Doman, Alexander G Shanku, Omar Davis, Nancy J Hauff, Yoram Sorokin, Xiaoquan Wen, et al.

    GWAS and eQTL studies identified thousands of genetic variants associated with complex traits and gene expression. Despite the important role of environmental exposures in complex traits, only a limited number of environmental factors are measured in these studies. Measuring molecular phenotypes in tightly controlled cellular environments provides a more tractable setting to study gene-environment interactions in the absence of other confounding variables. We performed RNA-seq and ATAC-seq in endothelial cells exposed to retinoic acid, dexamethasone, caffeine, and selenium to model genetic and environmental effects on gene regulation in the vascular endothelium, a common site of pathology in cardiovascular disease. We found that genes near regions of differentially accessible chromatin were more likely to be differentially expressed (OR = [3.41, 6.52], p < 10 −16 ). Furthermore, we confirmed that environment-specific changes in transcription factor binding are a key mechanism for cellular response to environmental stimuli. SNPs in these transcription response factor footprints for dexamethasone, caffeine, and retinoic acid were enriched in GTEx eQTLs from artery tissues indicating that these environmental conditions are latently present in GTEx samples. Additionally, SNPs in footprints for response factors in caffeine are enriched in colocalized eQTLs for coronary artery disease (CAD), suggesting a role for caffeine in CAD risk. Interestingly, each treatment may amplify or buffer genetic risk for CAD, depending on the particular SNP considered.


  • Antenatal Betamethasone for Women at Risk for Late Preterm Delivery

    by Cynthia Gyamfi-Bannerman, Elizabeth A. Thom, Sean C. Blackwell, Alan T. N. Tita, Uma M. Reddy, George R. Saade, Dwight J. Rouse, David S. McKenna, Erin A. S. Clark, John M. Thorp, et al.


  • Does the Presence of a Condition-Specific Obstetric Protocol Lead to Detectable Improvements in Pregnancy Outcomes?

    by Jennifer L. Bailit, William A. Grobman, Paula McGee, Uma M. Reddy, Ronald J. Wapner, Michael W. Varner, John M. Thorp, Kenneth J. Leveno, Jay D. Iams, Alan T. N. Tita, et al.

    In attempt to improve patient safety and outcomes, protocols for treatment of a specific complication have been suggested in various studies and encouraged by government regulation and malpractice carriers. However, evidence that condition-specific protocols improve obstetric outcomes is lacking. Studies that have shown improved outcomes because of these protocols have been primarily limited to single centers. This study examined if risk-adjusted patient outcomes would be better in hospitals with condition-specific obstetric protocols in place compared with hospitals without protocols. This study was a secondary analysis of the data set from a cohort study at 25 hospitals that was performed between 2008 and 2011, the Assessment of Perinatal Excellence (APEX) study. Participating hospitals submitted all protocols for labor and delivery quarterly and included the dates that those protocol were in effect. Patients were categorized by whether they delivered in the presence of a protocol. Data were analyzed to find whether the outcomes, adjusted for risk, related to specific complications were associated with condition-specific protocols used during deliver. Data from 115,502 patients were collected. The rate of hemorrhage was significantly higher in hospitals with a hemorrhage protocol. Hospitals without preeclampsia protocols had significantly higher rates of intensive care unit admissions for preeclampsia (odds ratio, 0.28; 95% confidence interval, 0.18–0.44), and preeclampsia-specific protocols were also associated with fewer cases of severe hypertension (odds ratio, 0.86; 95% confidence interval, 0.77–0.96). Protocols for postpartum hemorrhage were associated with an increased rate of postpartum hemorrhage and not associated with a lower rate of cases with more than 1000-mL estimated blood loss. Protocols for shoulder dystocia were not associated with a change in the rate of shoulder dystocia or rate of shoulder dystocia maneuvers used. There was not a consistent relationship found between condition-specific protocols and the severity of those complications. The adjustment for risk in these data was important for determining results. The different results found between preeclampsia protocols and hemorrhage protocols may be explained by the fact that preeclampsia is a more frequently occurring complication, and providers may be more familiar with that protocol. In conclusion, the results suggest whether a protocol is in place does not matter. More research is necessary to better understand high-quality protocol.


  • Umbilical Cord Serum Interleukin-6, C-Reactive Protein, and Myeloperoxidase Concentrations at Birth and Association with Neonatal Morbidities and Long-Term Neurodevelopmental Outcomes

    by Roberto Romero, Lisa Mele, Jay D. Iams, Alan M. Peaceman, Kenneth J. Leveno, Margaret Harper, Steve N. Caritis, Brian M. Mercer, John M. Thorp, Mary Jo O'Sullivan, et al.

    Objective The aim of the study is to determine if umbilical cord serum concentrations of interleukin-6 (IL-6), C-reactive protein (CRP), and myeloperoxidase (MPO), in pregnancies at risk for preterm birth (PTB), are associated with neonatal morbidities and/or altered neurodevelopmental outcomes in the children. Study Design Umbilical cord serum samples were collected at birth from 400 newborns delivered within a multicenter randomized controlled trial of repeated versus single course of antenatal corticosteroids (ACs), in women at increased risk for PTB. Newborns were followed through discharge and were evaluated between 36 and 42 months corrected age with neurological examination and Bayley Scales of Infant Development. Umbilical cord serum concentrations of IL-6, CRP, and MPO were determined using enzyme-linked immunoassays. Multivariate logistic regression analyses explored the relationship between umbilical cord serum IL-6, CRP, and MPO levels, adverse newborn outcomes, and PTB < 32 weeks of gestational age (GA). Results Univariate analysis revealed that umbilical cord IL-6 above the 75th percentile was associated with increased respiratory distress syndrome (RDS) and chronic lung disease (CLD), but not with necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), or neonatal sepsis; however, this association was not significant after adjusting for GA at delivery and treatment group. No significant associations between CRP or MPO and RDS, CLD, NEC, sepsis, or IVH were evident. Regression analysis revealed that CRP above the 75th percentile was associated with a decreased risk of CLD (odds ratio, 0.10; 95% confidence interval, 0.02–0.41). No associations between umbilical cord IL-6, CRP, or MPO and MDI < 70 or PDI < 70 were evident. Umbilical cord serum concentrations of IL-6, CRP, and MPO, above the 75th percentile, were associated with more frequent PTB < 32 weeks of GA. Conclusion Elevated umbilical cord serum concentration of CRP is associated with reduced risk for CLD even after adjusting for GA at delivery. Occurrence of levels > 75th percentile of IL-6, CRP, and MPO in umbilical cord serum was associated with PTB < 32 weeks of GA. Elevated umbilical cord serum concentrations of IL-6, CRP, and MPO at birth were not associated with poor neurodevelopmental outcomes.


  • Activity Restriction Among Women With a Short Cervix

    by William A. Grobman, Sharon A. Gilbert, Jay D. Iams, Catherine Y. Spong, George Saade, Brian M. Mercer, Alan T. N. Tita, Dwight J. Rouse, Yoram Sorokin, Kenneth J. Leveno, et al.

    Preterm birth remains a leading cause of perinatal morbidity and mortality, and prophylactic and therapeutic strategies have not reduced its frequency. Activity restriction specifically has not been beneficial and is associated with adverse social, economic, and health outcomes. This present secondary analysis of data from the Short Cervix and Nulliparity Trial was designed to estimate the determinants and outcomes of activity restriction in parturients with a short cervix. In the original randomized placebo-controlled trial, asymptomatic nulliparous women with singleton gestations and cervices of less than 30 mm received either weekly intramuscular 17-α hydroxyprogesterone caproate or placebo. During the weekly study visits, participants were asked whether pelvic rest (no sexual activity), reduction of work activity, or reduction of nonwork activity had been recommended. Women who had reductions in either pelvic, work, or nonwork activity were considered as having had “any” activity restriction. The association between activity restriction and preterm birth was determined at less than 37 and less than 34 weeks’ gestation. Multivariable analyses were performed with multiple logistic regression with odds ratios (ORs), adjusted ORs (aORs), and 95% confidence intervals (CIs) reported. All tests were 2 tailed, and P < 0.05 defined statistical significance. All analyses were performed with SAS version 9.2. Of the 657 women in the randomized trial, 646 (98%) responded to questions regarding activity restriction. Nearly 40% of women with a short cervix were placed on some activity restriction, usually in the midsecond to early third trimester, soon after the diagnosis of a short cervix was made. In 171 (68%) of 252 patients, all 3 types of activity restriction were combined. Compared with women without activity restriction, women who received recommendations for activity restriction were older (P < 0.001), more likely to have private insurance (P = 0.01), and less likely to be Hispanic white (P < 0.001); they also had shorter cervical lengths and were more likely to have cervical funneling or intra-amniotic debris. Preterm birth at less than 37 weeks’ gestation was significantly more common among women placed on any activity restriction (37% vs 17%, P < 0.001; OR, 2.91; 95% CI, 2.0–4.21). No significant interactions were found between activity restriction and treatment with 17-α hydroxyprogesterone caproate, cervical length of less than 15 mm, or gestational age at screening. After controlling for treatment group and demographic and ultrasonographic differences among those with and without activity restriction, preterm birth at less than 37 or less than 34 weeks’ gestation remained significantly more common among those placed on any activity restriction (aOR, 2.37; 95% CI 1.60–3.53 and aOR, 2.28, 95% CI, 1.36–3.80, respectively). Results were similar when only women prescribed limitation of work and nonwork activities were included in the restriction group (<37 weeks’ gestation: aOR, 2.44; 95% CI, 1.63–3.65; <34 weeks gestation: aOR, 2.70; 95% CI, 1.62–4.52). Some form of activity restriction was prescribed for more than 1 in every 3 nulliparous women with a short cervix. Activity restriction affected patients’ work and home life, and yet, they were still significantly more likely to deliver preterm. Activity restriction has been associated with increased stress and anxiety and increased chances of venous thromboembolism, bone loss, deconditioning, and financial difficulties. These complications and risk of preterm birth suggest that this intervention should be proven beneficial before it is used routinely for preterm birth prophylaxis.

  • Cytokine Gene Polymorphisms and Length of Gestation

    by Margaret Harper, S. Lilly Zheng, Elizabeth Thom, Mark A. Klebanoff, John Thorp, Yoram Sorokin, Michael W. Varner, Jay D. Iams, Mara Dinsmoor, Brian M. Mercer, et al.

  • Maternal Serum Interleukin-6, C-Reactive Protein, and Matrix Metalloproteinase-9 Concentrations as Risk Factors for Preterm Birth <32 Weeks and Adverse Neonatal Outcomes

    by Yoram Sorokin, Roberto Romero, Lisa Mele, Ronald Wapner, Jay Iams, Donald Dudley, Catherine Spong, Alan Peaceman, Kenneth Leveno, Margaret Harper, et al.

    Elevated concentrations of interleukin-6 (IL-6), C-reactive protein (CRP), and matrix metalloproteinase-9 (MMP-9) in fetal and neonatal compartments have been associated with an increased risk for preterm birth (PTB) and/or neonatal morbidity. The purpose of this study was to determine if the maternal serum concentration of IL-6, CRP, and MMP-9 in women at risk for PTB, who are not in labor and have intact membranes, are associated with an increased risk for PTB <32 weeks and/or neonatal morbidity. Maternal serum samples collected from 475 patients enrolled in a multicenter randomized controlled trial of single versus weekly corticosteroids for women at increased risk for preterm delivery were assayed. Serum was collected at randomization (24 to 32 weeks' gestation). Maternal serum concentrations of IL-6, CRP, and MMP-9 were subsequently determined using enzyme-linked immunoassays. Multivariate logistic regression analysis was performed to explore the relationship between maternal serum concentrations of IL-6, CRP, and MMP-9 and PTB <32 weeks, respiratory distress syndrome (RDS), chronic lung disease (CLD), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and any sepsis. Maternal serum concentrations of IL-6 and CRP, but not MMP-9, above the 90th percentile at the time of randomization were associated with PTB 90th percentile). However, there was no significant association after adjustment for GA at randomization and treatment group. Logistic regression analysis for each analyte indicated that high maternal serum concentrations of IL-6 and CRP, but not MMP-9, were associated with an increased risk of IVH (odds ratio [OR] 4.60, 95% confidence interval [CI] 1.86 to 10.68; OR 4.07, 95% CI 1.63 to 9.50) after adjusting for GA at randomization and treatment group. Most babies (25/30) had grade I IVH. When GA at delivery was included, elevated IL-6 remained significantly associated with IVH (OR 2.77, 95% CI 1.02 to 7.09). An elevated maternal serum concentration of IL-6 and CRP are risk factors for PTB <32 weeks and subsequent development of neonatal IVH. An elevated maternal serum IL-6 appears to confer additional risk for IVH even after adjusting for GA at delivery.


  • A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy

    by Dwight J. Rouse, Deborah G. Hirtz, Elizabeth Thom, Michael W. Varner, Catherine Y. Spong, Brian M. Mercer, Jay D. Iams, Ronald J. Wapner, Yoram Sorokin, James M. Alexander, et al.

    Early preterm birth is associated with approximately one third of all cases of cerebral palsy and is a risk factor. A case–control study was the first to show a decrease in the incidence of cerebral palsy in the offspring of women who were given magnesium sulfate before preterm delivery. This randomized, placebo-controlled, double-blind trial tested the hypothesis that antenatal administration of magnesium sulfate would reduce the incidence of cerebral palsy in the children of women at high risk for early preterm delivery. At 20 sites across the United States from December 1997 through May 2004, 2241 women at high risk for spontaneous delivery at 24 through 31 weeks’ gestation were randomized to receive either intravenous magnesium sulfate (6 gm infusion for 20 to 30 minutes followed by a maintenance infusion of 2 gm per hour) or a placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of age or moderate or severe cerebral palsy at or beyond 2 years of age. A trained psychologist or psychometrist administered and assessed scores on the Bayley Scales of Infant Development II. Baseline characteristics of the two groups were matched. Over 95% of the children were followed for 24 months. Corrections were made for prematurity. No significant differences were found for the primary composite outcome of moderate or severe cerebral palsy or death in the offspring of the magnesium sulfate group and the placebo group (11.3 versus 11.7%; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23; P = .80). However, women in the magnesium sulfate group had a significantly lower risk of giving birth to an infant who subsequently developed moderate or severe cerebral palsy than women in the placebo group (1.9% versus 3.5%, respectively; relative risk, 0.55; 95% CI, 0.32 to 0.95; P ≤ .03). There was no difference in scores on the Bayley scales of infant development between the two groups. No life threatening maternal events were noted in either group. This study is consistent with previous reports that antenatal magnesium sulfate does not reduce the combined risk of death or moderate or severe cerebral palsy, but may reduce the risk of cerebral palsy among survivors.

  • Long-Term Outcomes After Repeat Doses of Antenatal Corticosteroids

    by Ronald J. Wapner, Yoram Sorokin, Lisa Mele, Francee Johnson, Donald J. Dudley, Catherine Y. Spong, Alan M. Peaceman, Kenneth J. Leveno, Fergal Malone, Steve N. Caritis, et al.

  • A Trial of 17 Alpha-Hydroxyprogesterone Caproate to Prevent Prematurity in Twins

    by Dwight Rouse, Steve N. Caritis, Alan M. Peaceman, Anthony Sciscione, Elizabeth A. Thom, Catherine Y. Spong, Michael Varner, Fergal Malone, Jay D. Iams, Brian M. Mercer, et al.

    As recently as 2004, 12.5% of all live-born infants in the United States were delivered preterm, before 37 completed weeks of gestation. A recent trial showed that women with a previous spontaneous preterm birth who received weekly injections of 17 alpha-hydroxyprogesterone caproate (17P) had a one-third lower risk of recurrent preterm birth, but whether 17P can lower the rate in women with other risk factors is not clear. This placebo-controlled, double-blind, randomized, multicenter trial evaluated 17P in women carrying twins. Cases with serious fetal anomalies, detected by ultrasonography at 12–21 weeks' gestation, were excluded. Participants included 325 women given weekly intramuscular injections of 250 mg of 17P, starting at 16–20 weeks' gestation and ending at 35 weeks; and 330 placebo recipients. The primary outcome was delivery (or fetal death) before 35 weeks' gestation. Compliance rates approximated 95% in both groups. The primary outcomes were the same in the actively treated and control groups, with respective preterm delivery rates of 41.5% and 37.3% and a relative risk (RR) of 1.1 (95% confidence interval [CI], 0.9–1.3). Nearly three-fourths of deliveries taking place before 35 weeks' gestation were spontaneous rather than medically indicated. Intervals to pregnancy loss, fetal death, or delivery were similar in the treatment and control groups, as were rates of obstetrical interventions. Rates of a composite outcome of serious adverse fetal or neonatal events were 20.2% in the 17P group and 18.0% in the placebo group (RR, 1.1; 95% CI, 0.9–1.5). Nearly two-thirds of women in each group had side effects, but they were, in general, mild and limited to the injection site. The findings of this trial, which the investigators believe may be applied to most women in the US who are carrying twin pregnancies, fail to support the use of 17P for reducing the risk of preterm birth in twin gestations.